Advertisement
New Zealand markets closed

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NZD/USD

    0.5897
    -0.0008 (-0.14%)
     

  • NZD/EUR

    0.5527
    -0.0018 (-0.32%)
     

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • OIL

    83.32
    +0.59 (+0.71%)
     

  • GOLD

    2,408.50
    +10.50 (+0.44%)
     

  • NASDAQ

    17,192.33
    -201.99 (-1.16%)
     

  • FTSE

    7,895.42
    +18.37 (+0.23%)
     

  • Dow Jones

    37,932.35
    +156.97 (+0.42%)
     

  • DAX

    17,752.58
    -84.82 (-0.48%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • NZD/JPY

    91.0870
    -0.1670 (-0.18%)
     

Surface Oncology to Participate in Upcoming Investor Conferences

Surface Oncology, Inc.
·1-min read
Surface Oncology, Inc.
Surface Oncology, Inc.

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences:

  • A fireside chat at the UBS Global Healthcare Conference on Monday, May 23, 2022, at 2:45 p.m. ET in New York City.

  • A corporate presentation at the H.C. Wainwright Global Investment Conference. The prerecorded presentation will become available on-demand starting Tuesday, May 24, 2022, at 7 a.m. ET.

Archived webcasts of the fireside chat and on-demand corporate presentation will be accessible from the Events & Presentations page of the company's website.

ADVERTISEMENT

About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com